AbbVie Inc. $ABBV Shares Sold by South Dakota Investment Council

South Dakota Investment Council trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 7.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,871 shares of the company’s stock after selling 2,200 shares during the quarter. South Dakota Investment Council’s holdings in AbbVie were worth $6,222,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ABBV. Hutchinson Capital Management CA purchased a new position in shares of AbbVie during the third quarter worth about $212,000. Victory Capital Management Inc. lifted its position in AbbVie by 8.6% during the 3rd quarter. Victory Capital Management Inc. now owns 1,525,632 shares of the company’s stock worth $350,656,000 after acquiring an additional 120,490 shares during the period. Mathes Company Inc. purchased a new position in shares of AbbVie in the 3rd quarter valued at approximately $232,000. Accuvest Global Advisors increased its holdings in shares of AbbVie by 1.3% in the third quarter. Accuvest Global Advisors now owns 4,151 shares of the company’s stock valued at $961,000 after purchasing an additional 52 shares during the period. Finally, Focus Partners Advisor Solutions LLC increased its holdings in shares of AbbVie by 2.8% in the third quarter. Focus Partners Advisor Solutions LLC now owns 36,230 shares of the company’s stock valued at $8,203,000 after purchasing an additional 996 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Down 0.4%

Shares of AbbVie stock opened at $233.44 on Wednesday. The company has a 50-day moving average of $224.56 and a two-hundred day moving average of $223.66. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The stock has a market cap of $412.76 billion, a PE ratio of 98.92, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period last year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research report on Tuesday, November 4th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Citigroup dropped their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Barclays began coverage on shares of AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective for the company. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $258.00 target price on shares of AbbVie in a research report on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.